Ridgeback Biotherapeutics | search
Click here to view Ridgeback Biotherapeutics news from 60+ newspapers.
Bookmark or Share- EBANGA™ - Ridgeback BiotherapeuticsWendy Holman’s Ridgeback Biotherapeutics and Emergent BioSolutions Enter Into Agreement for Ebanga™ Treatment for Ebola
- Lagevrio (molnupiravir) - Ridgeback BiotherapeuticsRidgeback has completed Phase 1 and Phase 2 studies. The program has advanced into Phase 3 development as a therapeutic for COVID-19 and Lagevrio was found to significantly reduce the risk of hospitalization or death in an interim analysis of the Phase 3 MOVe-OUT trial.
- Contact Us - Ridgeback BiotherapeuticsFor general inquiries, call Ridgeback biotherapeutics on +1 786 687 2495 or email info@ridgebackbio.com. Learn more.
- Career Opportunities - Ridgeback BiotherapeuticsRidgeback Biotherapeutics commits resources and expertise for undefined and poorly understood diseases early in the pharmaceutical development cycle, at a time generally when few stakeholders are prepared to make the necessary commitments to develop treatments.
- Ridgeback BiotherapeuticsRidgeback Biotherapeutics develops potential medications to treat infectious diseases that have limited or no treatment options, like Ebola and COVID-19.
More
